select a format

Single User License
USD 3500 INR 227570
Site License
USD 7000 INR 455140
Corporate User License
USD 10500 INR 682710

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI)-Pipeline Review, H2 2016

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI)-Pipeline Review, H2 2016


  • Products Id :- GMDHC0706TDB
  • |
  • Pages: 35
  • |
  • December 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI)-Pipeline Review, H2 2016', provides in depth analysis on Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted pipeline therapeutics.

The report provides comprehensive information on the Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI)

The report reviews Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics and enlists all their major and minor projects

The report assesses Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics

Reasons to Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) Overview 6

Therapeutics Development 7

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI)-Products under Development by Stage of Development 7

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI)-Products under Development by Therapy Area 8

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI)-Products under Development by Indication 9

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI)-Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI)-Products under Development by Companies 12

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI)-Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI)-Companies Involved in Therapeutics Development 20

Bayer AG 20

Green Cross Corp 21

Novo Nordisk A/S 22

Pfizer Inc 23

Shire Plc 24

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI)-Drug Profiles 25

BAY-1093884-Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

concizumab-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

MG-1113A-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

PF-06741086-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Synthetic Peptide to Inhibit TFPI for Hemophilia-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI)-Dormant Projects 30

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI)-Discontinued Products 31

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI)-Featured News & Press Releases 32

Nov 30, 2015: New Data from Bayer's Portfolio in Hematology to be presented at ASH 2015 32

Oct 30, 2015: MorphoSys Announces Clinical Milestone in Hemophilia Program with Bayer HealthCare 33

Appendix 34

Methodology 34

Coverage 34

Secondary Research 34

Primary Research 34

Expert Panel Validation 34

Contact Us 34

Disclaimer 35

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Action, H2 2016 15

Number of Products by Routes of Administration, H2 2016 16

Number of Products by Stage and Routes of Administration, H2 2016 16

Number of Products by Molecule Types, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 18

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Action, H2 2016 15

Number of Products by Stage and Route of Administration, H2 2016 17

Number of Products by Stage and Molecule Type, H2 2016 19

Pipeline by Bayer AG, H2 2016 20

Pipeline by Green Cross Corp, H2 2016 21

Pipeline by Novo Nordisk A/S, H2 2016 22

Pipeline by Pfizer Inc, H2 2016 23

Pipeline by Shire Plc, H2 2016 24

Dormant Projects, H2 2016 30

Discontinued Products, H2 2016 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Bayer AG, Green Cross Corp, Novo Nordisk A/S, Pfizer Inc, Shire Plc

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) Therapeutic Products under Development, Key Players in Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) Therapeutics, Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) Pipeline Overview, Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) Pipeline, Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com